Safety and Radiosensitization of Olaparib with Radiotherapy in Triple-Negative Breast Cancer – ESTRO
European Society for Radiotherapy and Oncology (ESTRO) shared on LinkedIn:
“Long-term results from the RADIOPARP Phase I Trial: safety and radiosensitization of Olaparib with radiotherapy in triple-negative breast cancer patients, published in the Red Journal.
Read it before your patients.”
Title: Safety and potential radiosensitizing effect of Olaparib in combination with breast radiotherapy for TNBC patients with residual disease: long-term results from the RADIOPARP Phase I Trial: Safety and Radiosensitization of Olaparib with Radiotherapy in TNBC.
Journal: Red Journal
Authors: Pierre Loap, Delphine Loirat, Marc-Henri Stern, Jean-Yves Pierga, Kim Cao, Anne Vincent-Salomon, Frederique Berger, Alain Fourquet, Youlia Kirova
More posts featuring ESTRO on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023